The Annual General Meeting 2026 of RaySearch Laboratories AB (publ) was held on May 7, 2026 in Stockholm, Sweden. The following resolutions were adopted.
It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Britta Wallgren and Hans Wigzell as Board members of the company and to re-elect Hans Wigzell as Chairman of the Board.
The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from liability. It was resolved, in accordance with the Board's proposal, on a dividend of SEK 4 per share and that the remaining accumulated profit, amounting to SEK 238,326,992, be brought forward and balanced in the new accounts. The record date for the dividend was determined to be May 11, 2026.
It was resolved that remuneration to Board members who do not receive a salary from any Group company, shall amount to SEK 840,000 to the Chairman of the Board and SEK 300,000 to each of the other Board members elected by the general meeting.
It was resolved, in accordance with the Board's proposal, to re-elect the auditing firm Deloitte AB as auditor for the period until the next Annual General Meeting. Further, it was resolved that the auditor’s fees be paid in accordance with approved invoicing.
The Annual General Meeting also resolved to approve the Board's remuneration report for 2025 and to adopt the Board’s proposal for guidelines on executive remuneration.
The Annual General Meeting further resolved, in accordance with the Board's proposal, to establish a performance based long‑term incentive program (LTI 2026) and to authorise the Board, for the purpose of securing the company’s obligations under LTI 2026, to resolve on the acquisition and transfer of the company’s own shares of Class B to participants in LTI 2026.
The Annual General Meeting also resolved to authorise the Board, for the purpose of enabling a continuous adjustment of the company’s capital structure and thereby contributing to increased shareholder value, to resolve on acquisitions of the company’s own shares of Class B.
More information and complete documentation relating to the Annual General Meeting is available at www.raysearchlabs.com.
For more information, please contact:
Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information vsystems. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.